Literature DB >> 23078038

Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.

Rakesh Popat, Lenushka Maharaj, Heather Oakervee, Jamie Cavenagh, Simon Joel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23078038     DOI： 10.1111/bjh.12089

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  Not too little, not too much-just right! (Better ways to give high dose melphalan).

Authors:  P J Shaw; C E Nath; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

2.  Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.

Authors:  Toshihiro Miyamoto; Goichi Yoshimoto; Tomohiko Kamimura; Tsuyoshi Muta; Shuichiro Takashima; Yoshikiyo Ito; Motoaki Shiratsuchi; Ilseung Choi; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Yasushi Takamatsu; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

3.  Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.

Authors:  Jiro Kikuchi; Daisuke Koyama; Harumi Y Mukai; Yusuke Furukawa
Journal:  Int J Hematol       Date:  2014-04-06       Impact factor: 2.490

Review 4.  DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.

Authors:  Takayuki Saitoh; Tsukasa Oda
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.